Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight and Obese U.S. Adults
Response to Hoerger et al.
- Jaro Wex Wechowski, MD, PHD
- From Pharmarchitecture Limited, London, U.K.
- Corresponding author: Jaro Wex Wechowski, Pharmarchitecture Limited, Crusader House, 145-157 St. John St., London, EC1V 4PY, U.K. E-mail: jaro.wex{at}pharmarchitecture.com
I read with great interest the article by Hoerger et al. regarding cost-effectiveness of screening for pre-diabetes in the U.S. setting (1). The results reported by the authors have potentially global implications and should be viewed in the context of similar analyses conducted elsewhere.
The cost-effectiveness ratio obtained in the study is in broad agreement with recent findings for the U.K. (2). The U.K. analysis was based on a pre-diabetes screening module linked to a validated diabetes model (3). The value of the incremental cost-effectiveness ratio (ICER) was determined as £23,717 for patients with both impaired glucose tolerance and impaired fasting glucose treated with intensive …
